The Columbus Community Clinical Oncology Program (CCCOP) aims to reduce the morbidity and mortality from malignant disease through active participation in both cancer control and therapeutic research. Established in 1982, the CCCOP is a consortium of six health care systems encompassing eight acute care institutions. Fourteen medical oncologists, five radiation therapists, a surgical oncologist, four colorectal surgeons, general surgeons, internists, and family practitioners participate. Since the CCCOP was initially funded in 1983, we have established viable working relationships with the gamut of medical and surgical subspecialists as well as primary care physicians. The activities of the CCCOP are reported at the Cancer Committee meetings in all participating institutions, apprising the medical staffs of recent advances in oncology.
The specific aims of the Columbus CCOP include: 1) continued accrual of patients to the therapeutic clinical trials of the Southwest Oncology Group and the National Surgical Adjuvant Breast and Bowel Project; 2) maintenance of our excellent eligibility and evaluability rates; 3) extension of our well- developed methodology to the conduct of cancer control research in cooperation with M.D. Anderson Hospital and Tumor Institute; 4) continued extension of the advantages of treatment research and cancer control research to the underserved populations of central Ohio; 5) facilitating the direct involvement of primary are physicians in the conduct of research in prevention, detection, treatment, and continuing care; 6) maximizing the dissemination of advances in oncology to the primary care and medical subspecialists who play a major role in identifying populations at risk for malignancy, establishing screening interventions, diagnosing cancer, and determining initial treatment plans in the context of community medical practice. Through continuation of our consortium relationship, and our administrative structure, the Columbus Community Clinical Oncology Program can contribute to the reduction in the incidence, morbidity and mortality of cancer for the citizens of central Ohio.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035261-06
Application #
3557644
Study Section
(SRC)
Project Start
1983-09-30
Project End
1990-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
6
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Grant/Riverside Methodist Hospitals
Department
Type
DUNS #
City
Columbus
State
OH
Country
United States
Zip Code
43215
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32

Showing the most recent 10 out of 151 publications